Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group.

Beatriz Rey Búa Carlos Grande Jose Javier Sánchez Blanco Pau Abrisqueta Antonio Gutierrez Ángel R Payer Eva Giné Izaskun Zeberio Etxetxipia Maria José Terol Fátima de la Cruz Vicente Rafael Andreu María José Ramírez Adolfo de la Fuente María Cruz Viguria María Jesus Peñarrubia Ana Jiménez-Ubieto Santiago Montes Moreno Armondo López-Guillermo María Dolores Caballero Alejandro Martin Martin Garcia-Sancho

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Ibrutinib in combination with R-GemOx, followed by ibrutinib maintenance, demonstrated encouraging antitumor activity with durable responses and a manageable toxicity in patients with non-GCB DLBCL.

Keyphrases

diffuse large b cell lymphoma
phase ii
clinical trial
chronic lymphocytic leukemia
open label
epstein barr virus
phase iii
double blind
oxidative stress
placebo controlled
study protocol
randomized controlled trial